Skip to main content
Log in

Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: Life, scope, and value

  • Invited Commentary
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Dahlöf B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  Google Scholar 

  2. Lindholm LH, Ibsen H, Borch-Johnsen K, et al., for the LIFE Study Group: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879–1886.

    Article  PubMed  CAS  Google Scholar 

  3. Lindholm LH, Ibsen H, Dahlöf B, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  4. Kjeldsen SE, Dahlöf B, Deverux RB, et al., for the LIFE Study Group: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002, 288:1491–1498.

    Article  PubMed  CAS  Google Scholar 

  5. Lithell H, Hansson L, Skoog I, et al., for the SCOPE study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): prinicipal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875–886.

    Article  PubMed  CAS  Google Scholar 

  6. Mann J, Julius S, for the VALUE Trial Group: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998, 7:176–183.

    Article  PubMed  CAS  Google Scholar 

  7. Kjeldsen SE, Julius S, Brunner H, et al., for the VALUE Trial Group: Characteristics of 15314 hypertensive patients at high coronary risk: the VALUE trial. Blood Press 2001, 10:83–91.

    Article  PubMed  CAS  Google Scholar 

  8. Julius S, Kjeldsen SE, Weber M, et al., for the VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.

    Article  PubMed  CAS  Google Scholar 

  9. Weber M, Julius S, Kjeldsen SE, for the VALUE Trial Group: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049–2051.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kjeldsen, S.E., Westheim, A.S. & Os, I. Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: Life, scope, and value. Current Science Inc 7, 155–157 (2005). https://doi.org/10.1007/s11906-005-0001-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-005-0001-8

Keywords

Navigation